Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced its participation in the American College of Cardiology's 74th Annual Scientific Session & Expo (ACC.25), taking place March 29-31, 2025, at McCormick Place in Chicago, IL. Cardio Diagnostics will be exhibiting at Booth #2033, showcasing its growing portfolio of advanced cardiovascular solutions, focusing on the Company's PrecisionCHD™ test and its enhanced Actionable Clinical Intelligence (ACI™) report designed to transform how coronary heart disease (CHD) is diagnosed and managed.
Cardio Diagnostics' mission is to redefine cardiovascular care by combining epigenetics, genetics, and artificial intelligence to enable earlier detection of heart disease and more personalized patient management. Through our commitment to data-driven innovation, Cardio Diagnostics aims to prevent heart disease, improve diagnostic accuracy, and enable clinicians with actionable insights to deliver targeted, effective care.
Spotlight on PrecisionCHD™ and Actionable Clinical Intelligence (ACI™)
PrecisionCHD™, Cardio Diagnostics' flagship solution, is a clinical blood test available by prescription to aid in the diagnosis and management of coronary heart disease (CHD). Unlike traditional diagnostic tools, PrecisionCHD™ is radiation-free, requires no fasting, and is performed through a simple blood draw, either via standard phlebotomy or lancet-based sampling. By evaluating a unique panel of 10 genetic and 6 epigenetic (DNA methylation) markers, PrecisionCHD™ provides clinicians with deep insights into the unique underlying molecular drivers of CHD for each patient.
Importantly, the test results map epigenetic biomarkers to modifiable risk factors, allowing clinicians to personalize patient management. For cardiologists, PrecisionCHD™ serves as a critical tool in the fight against CHD, offering a non-invasive, radiation-free method to assess molecular drivers of CHD that traditional diagnostics may overlook. With the ability to track changes over time, PrecisionCHD™ empowers cardiologists to refine treatment plans based on a patient's unique epigenetic profile, ultimately driving more effective interventions and better long-term cardiovascular outcomes.
This year at ACC.25, Cardio Diagnostics will specifically highlight the updated Actionable Clinical Intelligence (ACI™) report for PrecisionCHD™, now enhanced to provide clearer, easier-to-interpret and more actionable clinical insights. The updated ACI™ leverages PrecisionCHD™'s six key methylation markers, giving prescribing clinicians sharper visibility into their patients' modifiable drivers of disease, including inflammation-related risk - a critical advancement for personalized care.
'PrecisionCHD™ and our enhanced Actionable Clinical Intelligence™ deliver a level of insight that no other solution offers cardiologists today,' said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. 'By integrating epigenetics, genetics, and AI, we provide a clearer, more actionable understanding of a patient's modifiable drivers of coronary heart disease. This empowers cardiologists to deliver truly personalized care and improve patient outcomes.'
Poster Presentation - Methylation Biomarkers as Predictors of Mortality in ACS Patients: A Critical Advancement for Clinical Cardiology
At ACC.25, Cardio Diagnostics will present compelling new data on the power of the methylation biomarkers of the PrecisionCHD™ test to predict mortality in patients with Acute Coronary Syndrome (ACS), offering cardiologists a novel, actionable tool to guide patient management to help improve survival outcomes.
The poster, titled 'Synergistic Effects of Combining Methylation Data with Imaging Data in Predicting Mortality of Acute Coronary Syndrome (ACS) Patients,' highlights findings from a recent study by Cardio Diagnostics demonstrating the superiority of PrecisionCHD methylation indices to angiographic methods for predicting mortality risk in ACS patients. In addition, the study delineates a machine learning-based method that could be integrated within existing electronic health records systems to synergistically combine angiographic and methylation information for predicting mortality risk.
By interrogating key methylation pathways linked to inflammation and coronary heart disease, PrecisionCHD™ can enable clinicians to more effectively stratify mortality risk and personalize treatment plans for ACS patients, potentially improving outcomes.
'These findings underscore the power of methylation-based biomarkers in cardiovascular medicine,' said Rob Philibert, M.D., Ph.D., Chief Medical Officer of Cardio Diagnostics. 'Traditional imaging tools provide valuable anatomical insights, but they fall short in predicting long-term mortality risk and providing mechanistic insights. Our study shows that methylation biomarkers not only fill this gap but also offer a more precise, biologically driven assessment of mortality risk, allowing cardiologists to intervene earlier and more effectively.'
Visit Cardio Diagnostics at Booth #2033
Attendees are invited to visit Booth #2033 to learn more about the Company's PrecisionCHD™, Epi+Gen CHD™ and Actionable Clinical Intelligence™ solutions, and its broader vision for AI-driven, epigenetic-guided precision cardiovascular medicine. The Company's executive team will also be onsite to engage with cardiologists, potential partners and attendees on how these innovations are transforming cardiovascular care.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ('Core Technology') for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/
Forward-Looking Statements
Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, under the heading 'Risk Factors' in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
Investor Relations
855-226-9991
[email protected] & Public Relations
Public Relations
855-226-9991
SOURCE: Cardio Diagnostics Holdings, Inc.
Copyright Business Wire 2025.
PUB: 03/26/2025 08:31 AM/DISC: 03/26/2025 08:32 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Confused by latest order? How to calculate if your Jackson County assessment is within limits
KANSAS CITY, Mo. — Jackson County assessments are showing up in homeowner's mailboxes. Some people may be surprised at the increase after a May order from the State Tax Commission. Some taxpayers may receive tax refunds in June: When payments could arrive That order capped increases in each assessment period at 15% and set 2022 as a starting point for this year's assessments after 2023 assessments were heavily contested. But determining your maximum 2025 assessment is a little bit more complicated than a single multiplication or division. Legislator Sean Smith and Preston Smith (no relation) have been helping homeowners with appeals since assessments skyrocketed in 2023. This week as they went out again they've been getting questions about what the latest State Tax Commission Order and 15% cap really means. 'People look at it and the first thing they see is, I thought it was only going to be a 15% increase and that was the perception. I've probably answered it online 100 times,' Preston Smith said. 'A lot of people are contacting me thinking they only do the 15 percent once, but you have to do it twice,' Legislator Sean Smith explained. To illustrate how it works with the latest rules using 2022 assessments as the starting point, consider a home with a $100,000 assessed value in 2022. To calculate the maximum assessed value in 2023 multiply $100,000 by 1.15 which is $115,000. But then you have to multiply by 115% again to determine the maximum value a home could be assessed at this year. In this example it would be $132,250. The two 15% increases end up yielding a maximum increase of 32.25% during the two assessment periods. 'I would really urge people to do the math themselves to check it, check and really verify,' Preston Smith said. To do that, however, you have to know your home's 2022 assessed value, which according to those who have received this year's assessments, isn't on this year's notices. You can find that historical information online at the Jackson County Parcel Viewer or Ascend Web. If your increase ends up beyond the allowances under the State order or if you simply don't agree with your value, you still can appeal. Appeals have to be filed by July 14. Download WDAF+ for Roku, Fire TV, Apple TV As for seniors, 40,000 are already enrolled in a new tax credit program freezing tax bills. The county says estimated savings are included on notices, but are subject to change. Both Sean and Preston Smith say they are pressing the Assessor's Office for complete assessment data in 2022, 2023 and 2025 to see how much home values increased, and how many of those increases equated to the maximum allowed if no new construction was done under the State Tax Commission Order without a physical inspection. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 hours ago
- Yahoo
A NEW ERA IN COLLEGE SPORTS BEGINS: COURT APPROVES LANDMARK HOUSE SETTLEMENT, NEW COLLEGE SPORTS COMMISSION LAUNCHES
WASHINGTON, June 6, 2025 /PRNewswire/ -- Today marks a historic milestone for college athletics in the United States. The U.S. District Court for the Northern District of California has granted final approval to a settlement in the House v. NCAA ("House") litigation. This landmark settlement – agreed to by plaintiffs representing nearly 400,000 current and former student-athletes and the NCAA, Atlantic Coast Conference (ACC), Big Ten Conference, Big 12 Conference, Pac-12 Conference and Southeastern Conference (SEC) – will reshape the landscape of college sports, paving the way for a model that prioritizes fairness, stability, integrity and opportunity for student-athletes and institutions. Overseeing this model will be the newly established College Sports Commission – an independent body that will be responsible for implementing the settlement terms governing revenue sharing, student-athlete Name, Image and Likeness (NIL) deals and roster limits. The Commission will investigate any potential violations of these rules, make determinations regarding potential rules violations and penalties, provide notice and opportunity to be heard, participate in the arbitration process and ultimately administer penalties for violations of these rules. The Commission's leadership team will be announced in the near future. Under the new system, student-athletes will have more opportunities to financially benefit during their participation in intercollegiate athletics than ever before. Institutions are now able to share revenue directly with student-athletes, in addition to providing existing benefits such as athletic scholarships, access to world-class training facilities, academic counseling, medical care, post-eligibility medical coverage, mental health resources, nutritional guidance and life skills development. Beginning July 1, 2025, each year, participating schools can distribute up to 22% of the average revenue among schools in the ACC, Big Ten, Big 12, Pac-12 and SEC from media rights, ticket sales, and sponsorships – known as the revenue sharing cap. The cap is estimated at $20.5 million per school for the 2025-26 academic year, pending final confirmation. To ensure revenue sharing with student-athletes is appropriately managed and reported to the Court for compliance, athletics departments will use the new College Athlete Payment System (CAPS) platform developed by LBi Software. Student-athletes will also be able to continue receiving compensation from third-parties other than their institutions for the use of their NIL, so long as their NIL deals are made with the purpose of using their NIL for a valid business purpose and do not exceed a reasonable range of compensation. On behalf of the College Sports Commission, Deloitte* has built and will maintain a new technology platform called NIL Go in which student-athletes will be required to report their NIL deals to confirm they are in compliance with the rules. Deals will be evaluated based on: Payor association – The relationship between the payor and the student-athlete's school. Valid business purpose – Whether the payor is seeking the use of the student-athlete's NIL for a valid business purpose, meaning to sell a good or service to the public for profit. Range of compensation – Whether the compensation paid to the student-athlete is commensurate with compensation paid to similarly situated individuals. Finally, for participating schools, NCAA scholarship limits have been removed and roster limits have been established for each sport, allowing for a significant increase in scholarship opportunities for student-athletes. Under this new model, schools will have the option to offer partial or full scholarships to every student-athlete on a team's roster, as long as the total number of student-athletes stays within the sport's specific roster limit. Efforts have also been made to ensure current and immediately incoming student-athletes are not adversely impacted by the establishing of roster limits. Removing scholarship limits allows schools to better support their student-athletes through new scholarships, particularly in non-revenue-generating sports. "This is a significant moment for college athletics that will provide unparalleled opportunities for student-athletes. We look forward to implementing this new system which offers much-needed transparency and structure to create a more sustainable model for the long-term future of college athletics," said Jim Phillips, Ph.D., Commissioner of the Atlantic Coast Conference. "We look forward to implementing this historic settlement designed to bring stability, integrity and competitive balance to college athletics while increasing both scholarship and revenue opportunities for student-athletes in all sports," said Tony Petitti, Commissioner of the Big Ten Conference. "As we enter this new era of college athletics, it is crucial we do so with structure, transparency, and the success of student-athletes in mind — this settlement and new model will ensure that happens. I look forward to working alongside my colleagues to implement this new system that prioritizes fairness and opportunity for all student-athletes and institutions," said Brett Yormark, Commissioner of the Big 12 Conference. "It's a new day in collegiate athletics. This historic moment allows us to maintain what makes college sports special, the development of young individuals through sport, while also evolving to meet today's student-athletes where they are with new opportunities in a manner that provides long-term stability for collegiate athletics. I am proud to work alongside my colleagues as we implement and introduce the future of college sports," said Teresa Gould, Commissioner of the Pac-12 Conference. "The approval of the House settlement agreement represents a significant milestone for the meaningful support of our student-athletes and a pivotal step toward establishing long-term sustainability for college sports, two of the Southeastern Conference's top priorities. As the journey to modernize collegiate sports continues, we remain focused on identifying and implementing innovative opportunities for our student-athletes across all sports while maintaining the core values that make collegiate athletics uniquely meaningful," said Greg Sankey, Commissioner of the Southeastern Conference. Following are significant dates related to the implementation of the settlement: June 6, 2025: Settlement approved; settlement-related NCAA rules are effective, as adopted by the NCAA Division 1 Board on April 21, 2025. June 11, 2025: NIL Go portal launches. June 15, 2025: Opt-in deadline for non-defendant schools to fully commit to revenue sharing. July 1, 2025: First date for direct institutional revenue sharing payments to student-athletes. July 6, 2025: Opt-in schools must "designate" student-athletes permitted by the settlement to remain above roster limits. Start of 2025-26 academic year: With the exception of the "designated" student-athletes, Fall sports must be at or below roster limits by their first day of competition. December 1, 2025: With the exception of "designated" student-athletes, Winter and Spring sports must be at or below roster limits by their first day of competition or Dec. 1, whichever is earlier. More information about the College Sports Commission and the implementation of these new policies can be found at * As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see for a detailed description of its legal structure. Certain services may not be available to attest clients under the rules and regulations of public accounting. MEDIA CONTACTcollegesportscommission@ View original content: SOURCE College Sports Commission Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
5 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
